Results of univariate analysis
| Variable . | No. . | OS at 1 y (P) . | PFS at 1 y (P) . | TRM at 1 y (P) . | Prog at 1 y (P) . | GVHD (P) . |
|---|---|---|---|---|---|---|
| Age | (.33) | (.49) | (.03)‡ | (.91) | (.09) | |
| Younger than 50 y | 144 | 65 | 50 | 22 | 33 | 38 |
| 50 y or older | 44 | 51 | 34 | 39 | 44 | 64 |
| Disease | (.04)‡ | (.009)‡ | (.08) | (.04)‡ | (.12) | |
| LGNHL | 52 | 73 | 61 | 22 | 21 | 48 |
| HGNHL | 62 | 52 | 32 | 30 | 47 | 52 |
| HD | 52 | 72 | 55 | 17 | 29 | 27 |
| MCL | 22 | 38 | 31 | 46 | 48 | 60 |
| Disease duration | (.37) | (.25) | (.046)‡ | (.85) | (.02)‡ | |
| Less than 2 y | 71 | 62 | 58 | 17 | 25 | 36 |
| 2–4 y | 63 | 54 | 35 | 35 | 42 | 54 |
| More than 4 y | 54 | 73 | 51 | 21 | 34 | 41 |
| Prior HDT | (.19) | (.08) | (.32) | (.33) | (.12) | |
| Yes | 97 | 56 | 41 | 30 | 36 | 49 |
| No | 91 | 68 | 52 | 21 | 33 | 39 |
| Disease chemosensitivity | (.004)‡ | (.005)‡ | (.06) | (.001)‡ | (.68) | |
| Chemosensitive | 133 | 67 | 55 | 25 | 23 | 48 |
| Chemoresistant4-150 | 40 | 42 | 19 | 28 | 71 | 41 |
| Remission | (.006)‡ | (.049)‡ | (.11) | (.67) | (.02)‡ | |
| Yes | 49 | 86 | 61 | 12 | 30 | 24 |
| No | 139 | 53 | 41 | 31 | 36 | 53 |
| Relationship to donor | (.47) | (.99) | (.13) | (.23) | (.22) | |
| Related | 171 | 63 | 46 | 23 | 37 | 43 |
| Unrelated | 17 | 60 | 60 | 40 | 0 | 46 |
| Infusion | (.76) | (.72) | (.90) | (.88) | (.88) | |
| PBSCs | 158 | 64 | 47 | 25 | 34 | 44 |
| BM4-151 | 29 | 52 | 41 | 22 | 34 | 45 |
| TCD | (.56) | (.21) | (.94) | (.24) | (.03)‡ | |
| Yes | 95 | 73 | 60 | 18 | 27 | 29 |
| No | 93 | 64 | 46 | 23 | 39 | 58 |
| Regimen intensity | (.91) | (.95) | (.38) | (.47) | (.24) | |
| Low | 51 | 61 | 40 | 24 | 44 | 44 |
| Intermediate | 118 | 62 | 50 | 28 | 29 | 48 |
| High | 19 | 63 | 51 | 22 | 29 | 17 |
| Variable . | No. . | OS at 1 y (P) . | PFS at 1 y (P) . | TRM at 1 y (P) . | Prog at 1 y (P) . | GVHD (P) . |
|---|---|---|---|---|---|---|
| Age | (.33) | (.49) | (.03)‡ | (.91) | (.09) | |
| Younger than 50 y | 144 | 65 | 50 | 22 | 33 | 38 |
| 50 y or older | 44 | 51 | 34 | 39 | 44 | 64 |
| Disease | (.04)‡ | (.009)‡ | (.08) | (.04)‡ | (.12) | |
| LGNHL | 52 | 73 | 61 | 22 | 21 | 48 |
| HGNHL | 62 | 52 | 32 | 30 | 47 | 52 |
| HD | 52 | 72 | 55 | 17 | 29 | 27 |
| MCL | 22 | 38 | 31 | 46 | 48 | 60 |
| Disease duration | (.37) | (.25) | (.046)‡ | (.85) | (.02)‡ | |
| Less than 2 y | 71 | 62 | 58 | 17 | 25 | 36 |
| 2–4 y | 63 | 54 | 35 | 35 | 42 | 54 |
| More than 4 y | 54 | 73 | 51 | 21 | 34 | 41 |
| Prior HDT | (.19) | (.08) | (.32) | (.33) | (.12) | |
| Yes | 97 | 56 | 41 | 30 | 36 | 49 |
| No | 91 | 68 | 52 | 21 | 33 | 39 |
| Disease chemosensitivity | (.004)‡ | (.005)‡ | (.06) | (.001)‡ | (.68) | |
| Chemosensitive | 133 | 67 | 55 | 25 | 23 | 48 |
| Chemoresistant4-150 | 40 | 42 | 19 | 28 | 71 | 41 |
| Remission | (.006)‡ | (.049)‡ | (.11) | (.67) | (.02)‡ | |
| Yes | 49 | 86 | 61 | 12 | 30 | 24 |
| No | 139 | 53 | 41 | 31 | 36 | 53 |
| Relationship to donor | (.47) | (.99) | (.13) | (.23) | (.22) | |
| Related | 171 | 63 | 46 | 23 | 37 | 43 |
| Unrelated | 17 | 60 | 60 | 40 | 0 | 46 |
| Infusion | (.76) | (.72) | (.90) | (.88) | (.88) | |
| PBSCs | 158 | 64 | 47 | 25 | 34 | 44 |
| BM4-151 | 29 | 52 | 41 | 22 | 34 | 45 |
| TCD | (.56) | (.21) | (.94) | (.24) | (.03)‡ | |
| Yes | 95 | 73 | 60 | 18 | 27 | 29 |
| No | 93 | 64 | 46 | 23 | 39 | 58 |
| Regimen intensity | (.91) | (.95) | (.38) | (.47) | (.24) | |
| Low | 51 | 61 | 40 | 24 | 44 | 44 |
| Intermediate | 118 | 62 | 50 | 28 | 29 | 48 |
| High | 19 | 63 | 51 | 22 | 29 | 17 |
The outcomes of overall survival (OS), progression free survival (PFS), transplant-related mortality (TRM), and disease progression (Prog) are given in percentages for each variable at 1 year after transplant. P values for the univariate log-rank test are given in parentheses.
HDT indicates high-dose therapy; PBSCs, peripheral blood stem cells; BM, bone marrow.
Fifteen patients were in untested relapse at the time of transplantation.
One patient received both PBSCs and BM.
Statistically significant.